Retirement Planning Co of New England Inc. Purchases New Position in Hologic, Inc. (NASDAQ:HOLX)

Retirement Planning Co of New England Inc. acquired a new position in Hologic, Inc. (NASDAQ:HOLX) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 4,500 shares of the medical equipment provider’s stock, valued at approximately $278,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Allworth Financial LP raised its position in Hologic by 46.0% in the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock valued at $40,000 after buying an additional 216 shares during the last quarter. EverSource Wealth Advisors LLC grew its stake in Hologic by 79.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 260 shares during the period. Larson Financial Group LLC boosted its holdings in shares of Hologic by 6,016.7% in the 1st quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider’s stock worth $45,000 after buying an additional 722 shares during the last quarter. Raiffeisen Bank International AG purchased a new stake in Hologic during the fourth quarter worth about $49,000. Finally, West Financial Advisors LLC purchased a new position in Hologic in the first quarter valued at about $50,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on HOLX shares. Evercore ISI lifted their price target on shares of Hologic from $62.00 to $68.00 and gave the stock an “in-line” rating in a report on Tuesday, July 8th. Raymond James Financial reaffirmed an “outperform” rating and set a $71.00 price target (down previously from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Stephens lowered their price objective on Hologic from $77.00 to $70.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 13th. Royal Bank Of Canada cut their target price on shares of Hologic from $75.00 to $70.00 and set a “sector perform” rating for the company in a research report on Friday, May 2nd. Finally, Mizuho lifted their price objective on shares of Hologic from $65.00 to $70.00 and gave the company an “outperform” rating in a research note on Wednesday. Eleven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $77.33.

Insiders Place Their Bets

In other news, Director Martin D. Madaus purchased 5,445 shares of the business’s stock in a transaction dated Wednesday, May 7th. The shares were purchased at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the acquisition, the director directly owned 5,445 shares in the company, valued at $300,781.80. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.88% of the company’s stock.

Hologic Stock Up 0.3%

NASDAQ:HOLX opened at $64.02 on Friday. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.24 and a quick ratio of 2.52. The firm’s 50-day moving average price is $62.31 and its 200-day moving average price is $63.30. The company has a market capitalization of $14.27 billion, a PE ratio of 27.01, a P/E/G ratio of 2.34 and a beta of 0.55. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.67.

Hologic (NASDAQ:HOLX) last announced its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 13.83% and a return on equity of 19.71%. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. During the same quarter last year, the firm earned $1.03 earnings per share. The business’s revenue for the quarter was down 1.2% on a year-over-year basis. On average, equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.